Amgen Released Phase 3 MINT Trial Data Evaluating the Efficacy and Safety of UPLIZNA® (inebilizumab-cdon)
The trial achieved its primary endpoint, as previously revealed at the 2024 American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting.
